KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(ttain peak annual sales of approximately...),Health

Date:2/15/2008

ttain peak annual sales of approximately $125 million for this product with gross margins consistent with those currently being achieved by Ther-Rx Corporation. The Company expects Evamist(TM) will significantly add to the women's health offerings of KV's branded subsidiary, Ther-Rx Corporation.

Acquisition of Gestiva(TM)

On January 22, 2008, the Company announced that it had entered into a definitive purchase agreement that gives KV full U.S. and worldwide rights to Gestiva(TM) (17-alpha hydroxyprogesterone caproate) upon approval of the pending Gestiva(TM) New Drug Application ("NDA"). The NDA for Gestiva(TM) is currently before the FDA, pending approval for use in the prevention of preterm birth in certain categories of pregnant women. The proposed indication is for women with a history of at least one spontaneous preterm delivery (i.e., less than 37 weeks), who are pregnant with a single fetus. The FDA issued an "approvable" letter for Gestiva(TM) in October 2006 and a final approval is anticipated in late 2008. The FDA has granted Orphan Drug Designation for Gestiva(TM). KV acquired Gestiva(TM) from Massachusetts-based Hologic, Inc. for $82 million in cash, $7.5 million of which was paid at closing. The balance is payable upon final FDA approval and the production of launch quantities. KV expects Gestiva(TM) to be accretive to KV's earnings in the first 12 months following its launch.

The Company believes that Gestiva(TM) will be an important extension to Ther-Rx's growing women's health franchise and believes that this acquisition will further support additional growth and profitability for the Company's branded business.

ETHEX Corporation - New Product Approvals Supporting Growth, Contributing 53.1% of Consolidated Corporate Revenues with Gross Margins of 58.7%

KV's specialty generic/non-branded subsidiary ETHEX Corporation, reported fiscal 2007 net revenues of $235.6 million, an increase of $31.8 million, or 15.6% compared
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
3. NUCRYST Pharmaceuticals announces year-end results
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
8. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
9. Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation
10. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
11. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program